Articles

Search Articles

Advanced search
Help

Catalogue

Articles

Databases

X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
oncology (45) 45
index medicus (24) 24
colorectal cancer (22) 22
colorectal neoplasms - drug therapy (17) 17
humans (17) 17
cancer (15) 15
care and treatment (14) 14
colorectal neoplasms - pathology (14) 14
metastasis (14) 14
metastatic colorectal cancer (14) 14
aged (12) 12
chemotherapy (12) 12
male (12) 12
bevacizumab (11) 11
female (11) 11
cetuximab (10) 10
colorectal neoplasms - genetics (10) 10
middle aged (10) 10
research (10) 10
colorectal neoplasms - mortality (9) 9
metastases (9) 9
analysis (8) 8
antineoplastic combined chemotherapy protocols - therapeutic use (8) 8
kras (8) 8
neoplasm metastasis (8) 8
camptothecin - analogs & derivatives (7) 7
colorectal carcinoma (7) 7
disease-free survival (7) 7
prognosis (7) 7
aged, 80 and over (6) 6
braf (6) 6
fluorouracil (6) 6
irinotecan (6) 6
mutation (6) 6
open-label (6) 6
patients (6) 6
proto-oncogene proteins b-raf - genetics (6) 6
receptor, epidermal growth factor - antagonists & inhibitors (6) 6
1st-line treatment (5) 5
adult (5) 5
angiogenesis (5) 5
antineoplastic combined chemotherapy protocols - adverse effects (5) 5
camptothecin - administration & dosage (5) 5
digestive system diseases (5) 5
genetic aspects (5) 5
leucovorin (5) 5
monoclonal antibodies (5) 5
panitumumab (5) 5
ras mutations (5) 5
ras proteins - genetics (5) 5
survival (5) 5
treatment outcome (5) 5
tumors (5) 5
usage (5) 5
anti-egfr monoclonal antibodies (4) 4
bevacizumab - therapeutic use (4) 4
cancer therapies (4) 4
clinical trials (4) 4
kaplan-meier estimate (4) 4
oxaliplatin (4) 4
progression-free survival (4) 4
proportional hazards models (4) 4
proto-oncogene proteins - genetics (4) 4
proto-oncogene proteins p21 (4) 4
therapy (4) 4
trial (4) 4
5-fluorouracil (3) 3
acquired-resistance (3) 3
antibodies, monoclonal, humanized - administration & dosage (3) 3
biochemistry & molecular biology (3) 3
biomarkers (3) 3
cancer patients (3) 3
cell biology (3) 3
colon-cancer (3) 3
colorectal neoplasms - blood (3) 3
combination (3) 3
deoxyribonucleic acid--dna (3) 3
diagnosis (3) 3
dna (3) 3
dna mutational analysis (3) 3
drug therapy (3) 3
epidermal growth factor (3) 3
expression (3) 3
fluorouracil - administration & dosage (3) 3
folfoxiri plus bevacizumab (3) 3
health aspects (3) 3
hematology, oncology and palliative medicine (3) 3
leucovorin - administration & dosage (3) 3
medicine & public health (3) 3
neoplasms (3) 3
non-inferiority (3) 3
oncology, experimental (3) 3
patient outcomes (3) 3
phase-3 trial (3) 3
prospective studies (3) 3
regorafenib (3) 3
resistance (3) 3
retrospective studies (3) 3
settore med/06 - oncologia medica (3) 3
survival analysis (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


1. Full Text FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study
by Cremolini, Chiara, MD and Loupakis, Fotios, PhD and Antoniotti, Carlotta, MD and Lupi, Cristiana, BSc and Sensi, Elisa, PhD and Lonardi, Sara, MD and Mezi, Silvia, MD and Tomasello, Gianluca, MD and Ronzoni, Monica, MD and Zaniboni, Alberto, MD and Tonini, Giuseppe, Prof and Carlomagno, Chiara, PhD and Allegrini, Giacomo, MD and Chiara, Silvana, MD and D'Amico, Mauro, MD and Granetto, Cristina, MD and Cazzaniga, Marina, MD and Boni, Luca, MD and Fontanini, Gabriella, Prof and Falcone, Alfredo, Prof
Lancet Oncology, The, ISSN 1470-2045, 2015, Volume 16, Issue 13, pp. 1306 - 1315
Summary Background In the TRIBE study, FOLFOXIRI (fluorouracil, leucovorin, oxaliplatin, and irinotecan) plus bevacizumab significantly improved... 
Hematology, Oncology and Palliative Medicine | TRIAL | CETUXIMAB | SURROGATE | LEUCOVORIN | ONCOLOGY | END-POINT | PROGRESSION-FREE SURVIVAL | RAS MUTATIONS | GUIDELINES | KRAS | FLUOROURACIL | Leucovorin - administration & dosage | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Bevacizumab - therapeutic use | Bevacizumab - adverse effects | Colorectal Neoplasms - genetics | Humans | Middle Aged | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Angiogenesis Inhibitors - administration & dosage | Neoplasm Metastasis | Organoplatinum Compounds - administration & dosage | Fluorouracil - administration & dosage | Time Factors | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Angiogenesis Inhibitors - therapeutic use | Camptothecin - administration & dosage | Female | Angiogenesis Inhibitors - adverse effects | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Bevacizumab - administration & dosage | Drug Administration Schedule | Kaplan-Meier Estimate | Proportional Hazards Models | Proto-Oncogene Proteins - genetics | Treatment Outcome | Disease-Free Survival | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Intention to Treat Analysis | Italy | Aged | Infusions, Intravenous | Mutation | Colorectal Neoplasms - pathology | Antimitotic agents | Cancer patients | Care and treatment | Patient outcomes | Analysis | Colorectal cancer | Leucovorin | Metastasis | Antineoplastic agents | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
2. Full Text Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
by Siravegna, Giulia and Mussolin, Benedetta and Buscarino, Michela and Corti, Giorgio and Cassingena, Andrea and Crisafulli, Giovanni and Ponzetti, Agostino and Cremolini, Chiara and Amatu, Alessio and Lauricella, Calogero and Lamba, Simona and Hobor, Sebastijan and Avallone, Antonio and Valtorta, Emanuele and Rospo, Giuseppe and Medico, Enzo and Motta, Valentina and Antoniotti, Carlotta and Tatangelo, Fabiana and Bellosillo, Beatriz and Veronese, Silvio and Budillon, Alfredo and Montagut, Clara and Racca, Patrizia and Marsoni, Silvia and Falcone, Alfredo and Corcoran, Ryan B and Di Nicolantonio, Federica and Loupakis, Fotios and Siena, Salvatore and Sartore-Bianchi, Andrea and Bardelli, Alberto
Nature Medicine, ISSN 1078-8956, 07/2015, Volume 21, Issue 7, pp. 795 - 801
Colorectal cancers (CRCs) evolve by a reiterative process of genetic diversification and clonal evolution. The molecular profile of CRC is routinely assessed... 
MEDICINE, RESEARCH & EXPERIMENTAL | BIOCHEMISTRY & MOLECULAR BIOLOGY | ACQUIRED-RESISTANCE | SENSITIVE DETECTION | DRUG-RESISTANCE | NUCLEIC-ACIDS | CELL BIOLOGY | KRAS MUTATIONS | HETEROGENEITY | DROPLET DIGITAL PCR | MELANOMA | THERAPY | FREE TUMOR DNA | Antibodies - therapeutic use | Receptor, Epidermal Growth Factor - genetics | Receptor, Epidermal Growth Factor - immunology | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Colorectal Neoplasms - blood | Antibodies, Neoplasm - blood | Colorectal Neoplasms - genetics | Humans | Proto-Oncogene Proteins - genetics | Antineoplastic Agents - therapeutic use | Mutation - genetics | Antibodies - pharmacology | Drug Resistance, Neoplasm - genetics | DNA, Neoplasm - blood | Colorectal Neoplasms - drug therapy | Alleles | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Antineoplastic Agents - pharmacology | Clone Cells | Colorectal Neoplasms - pathology | Clonal Evolution | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
3. Full Text Primary tumor location as a prognostic factor in metastatic colorectal cancer
by Loupakis, Fotios and Loupakis, Fotios and Yang, Dongyun and Yau, Linda and Feng, Shibao and Cremolini, Chiara and Zhang, Wu and Maus, Martin K. H and Antoniotti, Carlotta and Langer, Christiane and Scherer, Stefan J and Müller, Thomas and Hurwitz, Herbert I and Saltz, Leonard and Falcone, Alfredo and Lenz, Heinz-Josef
Journal of the National Cancer Institute, ISSN 0027-8874, 03/2015, Volume 107, Issue 3, p. 1
Background: We sought to clarify the prognostic impact of primary tumor location in metastatic colorectal cancer (mCRC). Methods: We evaluated the association... 
COLON-CANCER | SURVIVAL | EVOLUTION | PATTERN | ONCOLOGY | BEVACIZUMAB | 1ST-LINE THERAPY | EPIDEMIOLOGY | Colorectal Neoplasms - mortality | Predictive Value of Tests | Prognosis | Prospective Studies | Humans | Middle Aged | Kaplan-Meier Estimate | Proportional Hazards Models | Logistic Models | Male | Bevacizumab | Randomized Controlled Trials as Topic | Disease-Free Survival | Clinical Trials, Phase III as Topic | Antibodies, Monoclonal, Humanized - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Colorectal Neoplasms - drug therapy | Female | Aged | Colorectal Neoplasms - pathology | Neoplasm Staging | Odds Ratio | Chemotherapy | Metastasis | Analysis | Colorectal cancer | Cancer | Care and treatment | Survival analysis | Medical prognosis | Clinical trials | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
4. Full Text Erratum: Clonal evolution and resistance to EGFR blockade in the blood of colorectal cancer patients
by Siravegna, Giulia and Mussolin, Benedetta and Buscarino, Michela and Corti, Giorgio and Cassingena, Andrea and Crisafulli, Giovanni and Ponzetti, Agostino and Cremolini, Chiara and Amatu, Alessio and Lauricella, Calogero and Lamba, Simona and Hobor, Sebastijan and Avallone, Antonio and Valtorta, Emanuele and Rospo, Giuseppe and Medico, Enzo and Motta, Valentina and Antoniotti, Carlotta and Tatangelo, Fabiana and Bellosillo, Beatriz and Veronese, Silvio and Budillon, Alfredo and Montagut, Clara and Racca, Patrizia and Marsoni, Silvia and Falcone, Alfredo and Corcoran, Ryan B and Di Nicolantonio, Federica and Loupakis, Fotios and Siena, Salvatore and Sartore-Bianchi, Andrea and Bardelli, Alberto
Nature Medicine, ISSN 1078-8956, 07/2015, Volume 21, Issue 7, pp. 827 - 827
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
5. Full Text Role of NRAS mutations as prognostic and predictive markers in metastatic colorectal cancer
by Schirripa, Marta and Cremolini, Chiara and Loupakis, Fotios and Morvillo, Manfredi and Bergamo, Francesca and Zoratto, Federica and Salvatore, Lisa and Antoniotti, Carlotta and Marmorino, Federica and Sensi, Elisa and Lupi, Cristiana and Fontanini, Gabriella and Gregorio, Veronica De and Giannini, Riccardo and Basolo, Fulvio and Masi, Gianluca and Falcone, Alfredo
International Journal of Cancer, ISSN 0020-7136, 01/2015, Volume 136, Issue 1, pp. 83 - 90
NRAS mutations occur in 3–5% of colorectal cancer. Differently from KRAS and BRAF mutations, the role of NRAS mutations as prognostic and predictive markers in... 
metastatic colorectal cancer | NRAS | BRAF | KRAS | anti‐EGFR | anti-EGFR | 1ST-LINE TREATMENT | N-RAS | MICROSATELLITE INSTABILITY | KRAS WILD-TYPE | COLON-CANCER | PANITUMUMAB | K-RAS | ONCOLOGY | BRAF MUTATIONS | RAS MUTATIONS | CETUXIMAB PLUS IRINOTECAN | ras Proteins - genetics | Proto-Oncogene Proteins p21(ras) | Prognosis | Colorectal Neoplasms - genetics | Humans | Middle Aged | Male | Mutation, Missense | Liver Neoplasms - mortality | DNA Mutational Analysis | Antibodies, Monoclonal, Humanized - pharmacology | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Adult | Female | Retrospective Studies | Cetuximab | Liver Neoplasms - secondary | Colorectal Neoplasms - mortality | Antibodies, Monoclonal, Humanized - therapeutic use | Genetic Association Studies | Liver Neoplasms - genetics | Membrane Proteins - genetics | Kaplan-Meier Estimate | Liver Neoplasms - drug therapy | Proportional Hazards Models | Proto-Oncogene Proteins - genetics | Disease-Free Survival | Drug Resistance, Neoplasm - genetics | GTP Phosphohydrolases - genetics | Proto-Oncogene Proteins B-raf - genetics | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Aged | Biomarkers, Tumor - genetics | Colorectal Neoplasms - pathology | Chemotherapy | Gene mutations | Analysis | Colorectal cancer | Monoclonal antibodies | Genetic aspects | Metastasis | Cancer | Mutation | Medical prognosis | Tumors | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
6. Full Text First-line therapy for mCRC-the influence of primary tumour location on the therapeutic algorithm
by Cremolini, Chiara and Antoniotti, Carlotta and Moretto, Roberto and Masi, Gianluca and Falcone, Alfredo
Nature Reviews Clinical Oncology, ISSN 1759-4774, 02/2017, Volume 14, Issue 2, pp. 113 - 113
ONCOLOGY | BENEFIT | COLORECTAL-CANCER | Practice guidelines (Medicine) | Evaluation | Development and progression | Care and treatment | Colorectal cancer | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
7. Full Text A still missing piece of the FIRE-3 puzzle
by Antoniotti, Carlotta and Moretto, Roberto and Rossini, Daniele and Falcone, Alfredo and Cremolini, Chiara
Lancet Oncology, The, ISSN 1470-2045, 2016, Volume 17, Issue 12, pp. e515 - e515
Hematology, Oncology and Palliative Medicine | CETUXIMAB | COLORECTAL-CANCER FIRE-3 | ONCOLOGY | EARLY TUMOR SHRINKAGE | PHASE-3 TRIAL | OPEN-LABEL | FOLFIRI PLUS BEVACIZUMAB | DEPTH
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
8. Full Text The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab
by Demurtas, Laura and Puzzoni, Marco and Giampieri, Riccardo and Ziranu, Pina and Pusceddu, Valeria and Mandolesi, Alessandra and Cremolini, Chiara and Masi, Gianluca and Gelsomino, Fabio and Antoniotti, Carlotta and Loretelli, Cristian and Meriggi, Fausto and Zaniboni, Alberto and Falcone, Alfredo and Cascinu, Stefano and Scartozzi, Mario
British Journal of Cancer, ISSN 0007-0920, 07/2017, Volume 117, Issue 3, pp. 315 - 321
Background: The data from randomised trials suggested that primary tumour sidedness could represent a prognostic and predictive factor in colorectal cancer... 
LOCATION | colorectal cancer | ASSAY | RAS | IN-SITU HYBRIDIZATION | cetuximab | EGFR promoter methylation | BRAF | sidedness | IMPACT | ONCOLOGY | FREE SURVIVAL PFS | primary tumour location | MUTATION | ASSOCIATION | EXPRESSION | EGFR gene copy number | Leucovorin - administration & dosage | Follow-Up Studies | Colorectal Neoplasms - genetics | Humans | Male | DNA Methylation | Neoplasm Metastasis | Fluorouracil - administration & dosage | DNA Mutational Analysis | Colorectal Neoplasms - drug therapy | Camptothecin - administration & dosage | Female | DNA, Neoplasm - analysis | Retrospective Studies | Camptothecin - analogs & derivatives | Genes, ras - genetics | Promoter Regions, Genetic | Survival Rate | Gene Dosage | Disease-Free Survival | Retreatment | Genes, erbB-1 | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Proto-Oncogene Proteins B-raf - genetics | Cetuximab - administration & dosage | Aged | Colorectal Neoplasms - pathology | Therapy | Epidermal growth factor receptors | Copy number | Colorectal carcinoma | Colorectal cancer | Clinical trials | Multivariate analysis | Patients | Survival | Metastases | Irinotecan | Epidermal growth factor | Correlation analysis | Predictions | DNA methylation | Methylation | Tumors | Cancer | Index Medicus | Clinical Study
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
9. Full Text Prospective Validation of Candidate SNPs of VEGF/VEGFR Pathway in Metastatic Colorectal Cancer Patients Treated with First-Line FOLFIRI Plus Bevacizumab
by Loupakis, Fotios and Cremolini, Chiara and Yang, Dongyun and Salvatore, Lisa and Zhang, Wu and Wakatsuki, Takeru and Bohanes, Pierre and Schirripa, Marta and Benhaim, Leonor and Lonardi, Sara and Antoniotti, Carlotta and Aprile, Giuseppe and Graziano, Francesco and Ruzzo, Annamaria and Lucchesi, Sara and Ronzoni, Monica and de Vita, Ferdinando and Tonini, Giuseppe and Falcone, Alfredo and Lenz, Heinz-Josef
PLoS ONE, ISSN 1932-6203, 07/2013, Volume 8, Issue 7, pp. e66774 - e66774
Purpose: The potential impact of different SNPs of VEGF/VEGFR pathway on the clinical outcome of mCRC patients receiving bev-containing regimens has been... 
BIOMARKERS | LEUCOVORIN | CLINICAL-TRIAL DESIGNS | POLYMORPHISMS | MULTIDISCIPLINARY SCIENCES | PHASE-3 TRIAL | RESISTANCE | OXALIPLATIN | FLUOROURACIL | GENETIC-VARIATIONS | CHINESE POPULATION | Leucovorin - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - administration & dosage | Colorectal Neoplasms - genetics | Humans | Middle Aged | Neovascularization, Pathologic | Male | Vascular Endothelial Growth Factor A - genetics | Bevacizumab | Vascular Endothelial Growth Factor Receptor-2 - genetics | Neoplasm Metastasis | Fluorouracil - administration & dosage | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Angiogenesis Inhibitors - therapeutic use | Adult | Camptothecin - administration & dosage | Adenocarcinoma - genetics | Retrospective Studies | Drug Therapy, Combination | Camptothecin - analogs & derivatives | Colorectal Neoplasms - mortality | Gene Expression | Antibodies, Monoclonal, Humanized - therapeutic use | Colorectal Neoplasms - blood supply | Treatment Outcome | Adenocarcinoma - drug therapy | Sequence Analysis, DNA | Adenocarcinoma - blood supply | Survival Analysis | Aged | Polymorphism, Single Nucleotide | Adenocarcinoma - mortality | Care and treatment | Vascular endothelial growth factor | Analysis | Risk factors | Colorectal cancer | Impact prediction | Colorectal carcinoma | Clinical trials | Oncology | Single-nucleotide polymorphism | Metastasis | Cancer therapies | Patients | Metastases | Vascular endothelial growth factor receptors | Angiogenesis | Experimental design | Peripheral blood | Biomarkers | Population | Mathematical models | Deoxyribonucleic acid--DNA | Cancer | Index Medicus | Deoxyribonucleic acid | DNA
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
10. Full Text Phase II randomised study of maintenance treatment with bevacizumab or bevacizumab plus metronomic chemotherapy after first-line induction with FOLFOXIRI plus Bevacizumab for metastatic colorectal cancer patients: the MOMA trial
by Cremolini, Chiara and Marmorino, Federica and Bergamo, Francesca and Aprile, Giuseppe and Salvatore, Lisa and Masi, Gianluca and Dell’Aquila, Emanuela and Antoniotti, Carlotta and Murgioni, Sabina and Allegrini, Giacomo and Borelli, Beatrice and Gemma, Donatello and Casagrande, Mariaelena and Granetto, Cristina and Delfanti, Sara and Di Donato, Samantha and Schirripa, Marta and Sensi, Elisa and Tonini, Giuseppe and Lonardi, Sara and Fontanini, Gabriella and Boni, Luca and Falcone, Alfredo
European Journal of Cancer, ISSN 0959-8049, 03/2019, Volume 109, pp. 175 - 182
Alternating induction and maintenance phases is a common strategy in metastatic colorectal cancer (mCRC). Metronomic chemotherapy (metroCT) may represent a... 
Maintenance | FOLFOXIRI plus bevacizumab | Metronomic chemotherapy | Metastatic colorectal cancer | UFT | CYCLOPHOSPHAMIDE | INTERMITTENT | OXALIPLATIN | COMBINATION | NON-INFERIORITY | THERAPY | ONCOLOGY | KRAS | Cancer patients | Care and treatment | Chemotherapy | Art museums | Colorectal cancer | Metastasis | Cancer | Liver | Colorectal carcinoma | Patients | Survival | Subgroups | Bevacizumab | Metastases | Confidence intervals | Cyclophosphamide | Randomization | Mutation | Tumors
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
11. Full Text Pharmacokinetic analysis of metronomic capecitabine in refractory metastatic colorectal cancer patients
by Di Desidero, Teresa and Orlandi, Paola and Fioravanti, Anna and Cremolini, Chiara and Loupakis, Fotios and Marmorino, Federica and Antoniotti, Carlotta and Masi, Gianluca and Lonardi, Sara and Bergamo, Francesca and Zagonel, Vittorina and Falcone, Alfredo and Bocci, Guido
Investigational New Drugs, ISSN 0167-6997, 8/2018, Volume 36, Issue 4, pp. 709 - 714
The aim of the present study was to assess the pharmacokinetics (PK) of metronomic capecitabine and its metabolites in a population of refractory metastatic... 
Medicine & Public Health | Metronomic chemotherapy | Capecitabine | Oncology | Pharmacology/Toxicology | Pharmacokinetics | Metastatic colorectal cancer | METABOLITES | TOXICITY | CHEMOTHERAPY | 5-FLUOROURACIL | PLASMA | ENZYME | ONCOLOGY | 5'-DEOXY-5-FLUOROCYTIDINE | PHARMACOLOGY & PHARMACY | HUMAN LIVER | Chromatography, High Pressure Liquid - methods | Antimetabolites, Antineoplastic - pharmacokinetics | Area Under Curve | Colorectal Neoplasms - blood | Humans | Middle Aged | Floxuridine - pharmacokinetics | Male | Capecitabine - therapeutic use | Fluorouracil - therapeutic use | Antimetabolites, Antineoplastic - therapeutic use | Deoxycytidine - pharmacokinetics | Deoxycytidine - therapeutic use | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Female | Floxuridine - therapeutic use | Aged | Fluorouracil - pharmacokinetics | Deoxycytidine - analogs & derivatives | Capecitabine - pharmacokinetics | Cyclophosphamide | Usage | Chemotherapy | Metabolites | Analysis | Colorectal cancer | Dosage and administration | Diagnosis | Research | Drug therapy | Cancer | 5-Fluorouracil | Colorectal carcinoma | Pharmacology | Liquid chromatography | Metastasis | High-performance liquid chromatography | Patients | Metastases | Studies | High performance liquid chromatography | Index Medicus
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
12. Full Text Single‐Agent Panitumumab in Frail Elderly Patients With Advanced RAS and BRAF Wild‐Type Colorectal Cancer: Challenging Drug Label to Light Up New Hope
by Pietrantonio, Filippo and Cremolini, Chiara and Aprile, Giuseppe and Lonardi, Sara and Orlandi, Armando and Mennitto, Alessia and Berenato, Rosa and Antoniotti, Carlotta and Casagrande, Mariaelena and Marsico, Valentina and Marmorino, Federica and Cardellino, Giovanni Gerardo and Bergamo, Francesca and Tomasello, Gianluca and Formica, Vincenzo and Longarini, Raffaella and Giommoni, Elisa and Caporale, Marta and Di Bartolomeo, Maria and Loupakis, Fotios and Braud, Filippo
The Oncologist, ISSN 1083-7159, 11/2015, Volume 20, Issue 11, pp. 1261 - 1265
Unfit condition in frail elderly patients limits antineoplastic prescription and consequently patient survival. RAS and BRAF wild‐type status could help select... 
Elderly | Panitumumab | Metastatic colorectal cancer | Frail | 1ST-LINE TREATMENT | LEUCOVORIN | EFFICACY | BEVACIZUMAB | PHASE-II | FLUOROURACIL | TRIAL | CAPECITABINE | ONCOLOGY | CETUXIMAB PLUS IRINOTECAN | KRAS | Receptor, Epidermal Growth Factor - immunology | ras Proteins - genetics | Colorectal Neoplasms - genetics | Humans | Antibodies, Monoclonal - adverse effects | Kaplan-Meier Estimate | Male | Frail Elderly | Disease-Free Survival | Drug Labeling | Neoplasm Metastasis | Antibodies, Monoclonal - administration & dosage | Proto-Oncogene Proteins B-raf - genetics | Colorectal Neoplasms - drug therapy | Aged, 80 and over | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Female | Aged | Colorectal Neoplasms - pathology | Index Medicus | Geriatric Oncology | 6 | 8
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
13. Full Text NOS2 polymorphisms in prediction of benefit from first-line chemotherapy in metastatic colorectal cancer patients
by Schirripa, Marta and Zhang, Wu and Yang, Dongyun and Cao, Shu and Okazaki, Satoshi and Loupakis, Fotios and Berger, Martin D and Ning, Yan and Miyamoto, Yuji and Suenaga, Mitsukuni and Alberti, Giulia and West, Jordan D and Lonardi, Sara and Khoukaz, Taline and Bergamo, Francesca and Battaglin, Francesca and Antoniotti, Carlotta and Falcone, Alfredo and Stintzing, Sebastian and Heinemann, Volker and Lenz, Heinz-Josef
PLoS ONE, ISSN 1932-6203, 03/2018, Volume 13, Issue 3, pp. e0193640 - e0193640
Background Macrophages play a crucial role in the interaction between tumor and immune system, and iNOS is known as a surrogate marker of M1 macrophages... 
CETUXIMAB | LEUCOVORIN | NITRIC-OXIDE SYNTHASE | MULTIDISCIPLINARY SCIENCES | PHASE-3 TRIAL | TUMOR-ASSOCIATED MACROPHAGES | IRINOTECAN | OPEN-LABEL | FOLFIRI PLUS BEVACIZUMAB | FLUOROURACIL | EXPRESSION | Bevacizumab - pharmacology | Bevacizumab - therapeutic use | Prognosis | Colorectal Neoplasms - genetics | Humans | Middle Aged | Genotype | Male | Treatment Outcome | Clinical Trials as Topic | Colorectal Neoplasms - diagnosis | Neoplasm Metastasis | Nitric Oxide Synthase Type II - genetics | Colorectal Neoplasms - drug therapy | Female | Aged | Polymorphism, Single Nucleotide | Colorectal Neoplasms - pathology | Cohort Studies | Chemotherapy | Usage | Care and treatment | Colorectal cancer | Monoclonal antibodies | Dosage and administration | Research | Diagnosis | Macrophages | Genetic polymorphisms | Cancer | Test procedures | Colorectal carcinoma | Single-nucleotide polymorphism | Preventive medicine | Patients | Nitric-oxide synthase | Subgroups | Bevacizumab | Metastases | Gene sequencing | Cell activation | Nitric oxide | Health risk assessment | Deoxyribonucleic acid--DNA | DNA sequencing | Immune system | Index Medicus | Deoxyribonucleic acid | DNA
Journal Article
Details down arrow
Digital rights down arrow
loading Loading Rights
14. Full Text TRIBE-2: A phase III, randomized, open-label, strategy trial in unresectable metastatic colorectal cancer patients by the GONO group
by Cremolini, Chiara and Marmorino, Federica and Loupakis, Fotios and Masi, Gianluca and Antoniotti, Carlotta and Salvatore, Lisa and Schirripa, Marta and Boni, Luca and Zagonel, Vittorina and Lonardi, Sara and Aprile, Giuseppe and Tamburini, Emiliano and Ricci, Vincenzo and Ronzoni, Monica and Pietrantonio, Filippo and Valsuani, Chiara and Tomasello, Gianluca and Passardi, Alessandro and Allegrini, Giacomo and Di Donato, Samantha and Santini, Daniele and Falcone, Alfredo and Investigators Grp Oncologico and all the investigators of the Gruppo Oncologico del Nord Ovest and on behalf of all the investigators of the Gruppo Oncologico del Nord Ovest
BMC Cancer, ISSN 1471-2407, 06/2017, Volume 17, Issue 1, pp. 408 - 408
Background: Chemotherapy plus bevacizumab is a standard first-line treatment for unresectable metastatic colorectal cancer patients. Different chemotherapy... 
Folfoxiri | Clinical trial | Strategy | Colorectal cancer | Bevacizumab